Finfeed Archived May 26, 2021
Creso Pharma's target acquisition group Halucenex has entered into an agreement with consultancy group, HetereoGeneity
Finfeed Archived Mar 17, 2021
Creso Pharma's targeted acquisition, Halucenex Life Sciences has appointed True North Clinical Research to conduct PTSD trials
Get expert stock analysis direct in your inbox
Join OurMailing List
